Literature DB >> 31079333

Development of bacteria as diagnostics and therapeutics by genetic engineering.

Daejin Lim1, Miryoung Song2.   

Abstract

Bacteria sense and respond to the environment, communicate, and continuously interact with their surroundings, including host bodies. For more than a century, engineers have been trying to harness the natural ability of bacteria as live biotherapeutics for the treatment of diseases. Recent advances in synthetic biology facilitate the enlargement of the repertoire of genetic parts, tools, and devices that serve as a framework for biotherapy. This review describes bacterial species developed for specific diseases shown in in vitro studies and clinical stages. Here, we focus on drug delivery by programing bacteria and discuss the challenges for safety and improvement.

Keywords:  drug delivery; engineered bacteria; live biotherapy; synthetic biology

Mesh:

Year:  2019        PMID: 31079333     DOI: 10.1007/s12275-019-9105-8

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  84 in total

1.  Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent.

Authors:  D A Saltzman; C P Heise; D E Hasz; M Zebede; S M Kelly; R Curtiss; A S Leonard; P M Anderson
Journal:  Cancer Biother Radiopharm       Date:  1996-04       Impact factor: 3.099

2.  Dual system to reinforce biological containment of recombinant bacteria designed for rhizoremediation.

Authors:  M C Ronchel; J L Ramos
Journal:  Appl Environ Microbiol       Date:  2001-06       Impact factor: 4.792

3.  Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector.

Authors:  L M Zheng; X Luo; M Feng; Z Li; T Le; M Ittensohn; M Trailsmith; D Bermudes; S L Lin; I C King
Journal:  Oncol Res       Date:  2000       Impact factor: 5.574

4.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.

Authors:  S C Liu; N P Minton; A J Giaccia; J M Brown
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

Review 5.  Immune responses to Listeria monocytogenes.

Authors:  Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

6.  In situ delivery of passive immunity by lactobacilli producing single-chain antibodies.

Authors:  Carina Krüger; Yanzhong Hu; Qiang Pan; Harold Marcotte; Anna Hultberg; Dipu Delwar; Philip J van Dalen; Peter H Pouwels; Rob J Leer; Charles G Kelly; Craig van Dollenweerd; Julian K Ma; Lennart Hammarström
Journal:  Nat Biotechnol       Date:  2002-07       Impact factor: 54.908

7.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.

Authors:  Lothar Steidler; Sabine Neirynck; Nathalie Huyghebaert; Veerle Snoeck; An Vermeire; Bruno Goddeeris; Eric Cox; Jean Paul Remon; Erik Remaut
Journal:  Nat Biotechnol       Date:  2003-06-15       Impact factor: 54.908

8.  Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria.

Authors:  Stefano Porzio; Paola Bossù; Paolo Ruggiero; Diana Boraschi; Aldo Tagliabue
Journal:  BMC Biotechnol       Date:  2004-10-30       Impact factor: 2.563

9.  A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans.

Authors:  A W Paton; R Morona; J C Paton
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

10.  In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.

Authors:  Susanna Ricci; Giovanni Macchia; Paolo Ruggiero; Tiziana Maggi; Paola Bossù; Li Xu; Donata Medaglini; Aldo Tagliabue; Lennart Hammarström; Gianni Pozzi; Diana Boraschi
Journal:  BMC Biotechnol       Date:  2003-09-17       Impact factor: 2.563

View more
  1 in total

Review 1.  Bacteria and cells as alternative nano-carriers for biomedical applications.

Authors:  Rafaela García-Álvarez; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2022-01-25       Impact factor: 6.648

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.